Boston Scientific Stock Faces Headwinds, But Upside Potential Remains

The medical device maker's shares have fallen 33% this year, but its fundamentals remain strong compared to peers.

Mar. 31, 2026 at 10:04am

Got story updates? Submit your updates here. ›

Boston Scientific (BSX) has seen its stock price drop by a third so far in 2026, including a 9% single-day decline on March 30. This was triggered by mixed trial results for its Watchman FLX device and other issues, but the company's overall revenue growth, margins, and balance sheet remain strong compared to competitors like Medtronic and Abbott. At the current valuation of 18.1x forward earnings, well below its historical average, the stock could surge 40% if it can resolve its recent setbacks and return to its previous premium valuation.

Why it matters

Boston Scientific is a leading medical device company with a track record of consistent double-digit revenue growth. Its recent stock price decline represents a potential buying opportunity for investors if the company can overcome its near-term challenges and regain investor confidence in its growth trajectory.

The details

The immediate trigger for Boston Scientific's stock drop was disappointing trial data for its Watchman FLX device, which showed a slightly higher ischemic stroke rate compared to standard blood thinners. This, combined with weaker-than-expected Q1 2026 guidance, a recall of its Accolade pacemaker line, and dilution from its $14.5 billion Penumbra acquisition, has led to a significant repricing of the stock. However, the company's fundamentals remain strong, with 16.6% average annual revenue growth over the past three years, operating margins in line with peers, and a relatively low debt load.

  • On March 30, 2026, Boston Scientific's stock price dropped 9% in a single trading session.
  • In Q4 2025, Boston Scientific beat revenue and EPS estimates but provided Q1 2026 guidance that fell short of expectations.

The players

Boston Scientific

A leading global medical device company that develops, manufactures and markets a broad range of medical devices used in various interventional medical specialties.

Medtronic

A global medical technology company that develops and manufactures innovative therapeutic medical devices, including pacemakers, defibrillators, and other products.

Abbott

A diversified global healthcare company that develops and manufactures a broad range of medical devices, diagnostic products, nutritional goods, and branded generic pharmaceuticals.

Got photos? Submit your photos here. ›

What they’re saying

“The immediate trigger was CHAMPION-AF trial data for the Watchman FLX device. The trial met its endpoints, but the device showed a slightly higher ischemic stroke rate versus standard blood thinners.”

— Trefis Team, Author

What’s next

Boston Scientific will need to leverage its successful CHAMPION-AF presentation at ACC.26 to secure expanded guideline inclusions for the Watchman device as a premier alternative to direct oral anticoagulants (DOACs). The company must also deliver positive results from its AVANT GUARD trial to expand the use of its FARAPULSE technology for the treatment of persistent atrial fibrillation. Additionally, Boston Scientific will need to prove that its $14.5 billion acquisition of Penumbra will transition from initial EPS dilution to becoming an accretive earnings driver by the second year.

The takeaway

Despite the recent stock price decline, Boston Scientific remains a high-quality medical device company with a strong track record of revenue growth and profitability. At the current valuation, the stock appears underpriced compared to its peers, offering an attractive entry point for long-term investors if the company can successfully navigate its near-term challenges.